BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230308
DTEND;VALUE=DATE:20230310
DTSTAMP:20260516T051036
CREATED:20221215T131203Z
LAST-MODIFIED:20221215T131251Z
UID:36101-1678233600-1678406399@www.pharmajournalist.com
SUMMARY:Targeted Intracellular Delivery Summit
DESCRIPTION:Achieve Therapeutic Localization with Selective\, Effective & Validated Delivery to Intracellular Targets \nOptimize Your Pipeline’s Therapeutic Index with Novel Delivery Systems to Overcome Endosomal Barriers in Target Cells \nSelective cell entry\, biological barriers and complexities in targeting chemistry have long restricted the ability of promising drug candidates to impactfully engage their intracellular sites of action without off-target toxicity implications. \nFast forward to 2023\, advances in nanomedicine technology\, the LNP enabled mRNA vaccine and emphasis on personalized medicine has triggered significant pipeline shifts towards complex nucleic-acid and biologic candidates. This clinical translation depends on novel delivery systems accessing previously elusive intracellular compartments. This is further evidenced by AstraZeneca\, Boehringer Ingelheim and Eli Lilly’s announcements of prioritized strategic investment in targeted intracellular delivery technologies. \nAt such a pivotal moment for the industry\, the Targeted Intracellular Delivery Summit arrives to bring Formulation\, Chemistry\, Delivery & Biology industry professionals to the forefront of cutting-edge science critical to accelerate pharmaceutical R&D. Join 80+ senior leaders to explore target identification\, tissue delivery\, engineering technologies\, endosomal escape\, delivery validation analytics and more. \nThis is your definitive meeting for unpresented data\, unrivalled insights and unmissable methodologies across the next-generation nano-platforms including LNPs\, EVs\, Liposomes & more\, creating new opportunities for the development of safer and efficacious oligonucleotide\, siRNA\, mRNA\, DNA delivery and protein payloads. \nUnleash the true potential of your pipeline by gaining the best picture of industry’s fast-paced nano-platform progress this March! \nTo know more visit: https://ter.li/i23a5q
URL:https://www.pharmajournalist.com/event/targeted-intracellular-delivery-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230313
DTEND;VALUE=DATE:20230315
DTSTAMP:20260516T051036
CREATED:20221213T115004Z
LAST-MODIFIED:20221213T115004Z
UID:36069-1678665600-1678838399@www.pharmajournalist.com
SUMMARY:SAE Media Group Proudly Presents the 4th Annual AI in Drug Discovery Conference
DESCRIPTION:SAE Media Group is proud to present its 4th Annual AI in Drug Discovery Conference\, taking place from 13 – 14 March 2023 in London\, UK. \nWith the recent pandemic highlighting the need for rapid drug discovery\, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning. The current challenges within the drug discovery industry include the significant time consumption and expenses involved. This conference will discuss the solutions to these problems with presentations and updates from leading industry experts. \nAI in drug discovery is leading the way into a shorter\, cheaper and more successful R&D era where compound generation is automated\, drug synthesis is predictable and undruggable diseases are finally being targeted. \nThe uptake of structure-based target selection and innovative in-silico techniques are driving optimised\, more efficient drug discovery. This\, alongside sessions on automation\, robotics and how to improve patient-centricity in precision medicine are just some of the topics set to be discussed which you wouldn’t want to miss at the 4th annual AI in Drug Discovery Conference 2023. \nOur influential line-up of speakers will be taking to the stage from 13 – 14 March 2023 at the Copthorne Tara Hotel\, London to provide you with the latest insights and advice for you to take back to your business. \nKey Reasons to Attend: \n\nDELVE into key industry research focuses\, with talks on fragment-based selection\, in silico drug design and personalised medicine from GSK\, Bayer\, Janssen Pharmaceuticals and more\nINCREASE the diversity of your drug discovery programme with case studies in applying knowledge graphs\, molecular dynamic simulations\, and digital twins throughout the development process\nUTILISE breakthroughs in robotics\, automation and quantum chemical methods alongside AI to drive the next generation of drug discovery\nUNCOVER the role that international cooperation and open-source data played in the rapid development of Covid-19 treatments\, and how this can be an example for the future of pharmaceutical R&D\nLEARN how to implement AI and Machine Learning techniques throughout the discovery pipeline from antigens and genomics to proteins and peptides\n\nTo know more visit: www.ai-indrugdiscovery.com/PJ-EL
URL:https://www.pharmajournalist.com/event/4th-annual-ai-in-drug-discovery-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SAE Media Group":MAILTO:Hannah.blake@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230320
DTEND;VALUE=DATE:20230324
DTSTAMP:20260516T051036
CREATED:20221124T112949Z
LAST-MODIFIED:20221124T112949Z
UID:35918-1679270400-1679615999@www.pharmajournalist.com
SUMMARY:6th Annual Gene Therapy for Rare Disorders 2023 Summit
DESCRIPTION:As the gene therapy field continues to break records\, there are still significant challenges to overcome relating to safety\, efficacy\, and accessibility. The 6th Annual Gene Therapy for Rare Disorders 2023 Summit remains devoted to showcasing the top case studies and strategic learnings from the past year. With an expert speaking faculty devoted to bringing safer and more effective gene therapies to rare disease patients\, key questions will be answered on how best the field can overcome regulatory\, clinical\, manufacturing and pricing bottlenecks to progress gene therapies into and through the clinic. \n500+ leading experts from innovative biotechs\, large pharma\, academia and key service providers will be reuniting in Boston for 2023 to capitalize on recent success stories and collaborate over the most pressing industry challenges. An event vital to unlocking the full potential of your rare gene therapy program\, join us to keep your finger on the pulse and set up for success in 2023. \nTo know more visit: https://ter.li/bvmkei
URL:https://www.pharmajournalist.com/event/6th-annual-gene-therapy-for-rare-disorders-2023-summit/
LOCATION:Sheraton Boston Hotel\, 39 Dalton Street\, Boston\, MA\, 02199\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230328
DTEND;VALUE=DATE:20230330
DTSTAMP:20260516T051036
CREATED:20221213T120801Z
LAST-MODIFIED:20221213T120801Z
UID:36077-1679961600-1680134399@www.pharmajournalist.com
SUMMARY:Reuters Events: Pharma USA 2023
DESCRIPTION:Patient-first. Collaborative. Data and insights driven. Digitally underpinned. \nThese are the qualities of a healthcare system that actively serves its purpose – yet instead\, the US is hindered by mounting financial toxicity\, unprecedented politicization of science and eroding public trust. \nTo capitalize on three years of extraordinary momentum and lead healthcare’s reform\, pharma must embody the traits that healthcare needs to thrive and restructure in pursuit of change. \nSeize the moment at Reuters Events: Pharma USA 2023 to lead pharma’s internal revolution and drive this critical systemic transformation. Join North America’s visionary pharma changemakers\, leading solution providers\, patient experts and industry heavyweights to catapult commercial excellence\, ingrain patient-first strategies into the heart of pharma’s fabric and heed the long-awaited rebirth of America’s healthcare system. \nTo know more visit: https://bit.ly/3uJUp5O
URL:https://www.pharmajournalist.com/event/reuters-events-pharma-usa-2023/
LOCATION:Pennsylvania Convention Center\, 1101 Arch St\, Philadelphia\, PA\, 19107\, United States
ORGANIZER;CN="Reuters Events":MAILTO:Tahmeena.Miah@ThomsonReuters.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230328
DTEND;VALUE=DATE:20230331
DTSTAMP:20260516T051036
CREATED:20230310T091100Z
LAST-MODIFIED:20230310T091100Z
UID:36791-1679961600-1680220799@www.pharmajournalist.com
SUMMARY:8th Innate Killer Summit
DESCRIPTION:Dedicated to driving cost-effective\, efficacious\, safe\, durable\, scalable\, and globally accessible allogeneic\, cell-based\, and engager therapies\, the 8th Innate Killer Summit returns to cement your end-to-end education in innate immune therapeutics. Your industry-defining Innate Killer Summit brings crucial insights for everyone on your team\, with 4 content tracks spanning preclinical development\, clinical translation\, CMC\, process development\, and clinical scale manufacturing\, this is the definitive meeting to drive concept to commercial success of emerging innate immune therapies. \nDownload your copy of the Full Event Guide here. \nJoin over 250 experts from 120+ pioneering companies to drive novel gene engineering technologies\, gain regulatory know-how\, optimize lymphodepletion and cryopreservation\, and contrast cell sources for highly efficacious\, scalable off-the-shelf therapies. \nPromising brand-new speakers from new companies\, interactive discussion\, and engaging networking opportunities\, attend to forge new collaborations and realize the clinical potential of innate immune therapies. \nRegister your place here.
URL:https://www.pharmajournalist.com/event/8th-innate-killer-summit/
LOCATION:HILTON LA JOLLA TORREY PINES\, 10950 N. Torrey Pines Road\, La Jolla\, CA\, 92037\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR